Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy

PRINCETON, N.J.; TOKYO, JAPAN; WALTHAM, MA. February 16, 2024– Otsuka Pharmaceutical Development& Commercialization, Inc., (OPDC); Otsuka Pharmaceutical, Co. Ltd. (Otsuka); and Visterra, Inc., an Otsuka group company announce that the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials